Predictive Oncology Files 8-K on Shareholder Vote Submission
Ticker: AGPU · Form: 8-K · Filed: Jan 4, 2024 · CIK: 1446159
Complexity: simple
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, 8-K
TL;DR
**Predictive Oncology filed an 8-K about a shareholder vote, but the results aren't in this filing.**
AI Summary
Predictive Oncology Inc. filed an 8-K on January 4, 2024, reporting on matters submitted to a vote of security holders on December 28, 2023. This filing, under Item 5.07, indicates that the company held a vote, though the specific outcomes or proposals are not detailed in this particular excerpt. For investors, this means the company is adhering to regulatory requirements by disclosing that a shareholder vote occurred, but without knowing the results, it's hard to gauge the immediate impact on the stock.
Why It Matters
This filing confirms that Predictive Oncology Inc. held a shareholder vote, which is a routine corporate governance event. Investors need to see the results of this vote to understand any potential changes to the company's structure or operations.
Risk Assessment
Risk Level: low — This filing is a standard disclosure of a corporate event (shareholder vote) and does not inherently present new risks or opportunities without the vote's outcome.
Analyst Insight
A smart investor would note this filing but await a subsequent 8-K or proxy statement that details the specific proposals voted on and the outcomes of the shareholder vote before making any investment decisions.
Key Players & Entities
- Predictive Oncology Inc. (company) — the registrant filing the 8-K
- December 28, 2023 (date) — date of the earliest event reported (shareholder vote)
- January 4, 2024 (date) — date the 8-K was filed
- Delaware (company) — state of incorporation for Predictive Oncology Inc.
- 001-36790 (dollar_amount) — Commission File Number
FAQ
What is the purpose of this 8-K filing by Predictive Oncology Inc.?
The purpose of this 8-K filing, dated January 4, 2024, is to report on the 'Submission of Matters to a Vote of Security Holders' that occurred on December 28, 2023, as per Item 5.07 of Form 8-K.
When did the event reported in this 8-K take place?
The earliest event reported in this 8-K took place on December 28, 2023, which is the date the matters were submitted to a vote of security holders.
What is the full legal name of the company filing this 8-K?
The exact name of the registrant as specified in its charter is Predictive Oncology Inc.
Where is Predictive Oncology Inc. incorporated?
Predictive Oncology Inc. is incorporated in Delaware.
What is the business address of Predictive Oncology Inc.?
The business address of Predictive Oncology Inc. is 91 43rd Street, Suite 110, Pittsburgh, Pennsylvania 15201.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 9.5 · Accepted 2024-01-04 17:00:16
Key Financial Figures
- $0.01 — nge on which registered Common stock, $0.01 par value POAI NASDAQ Capital Market
Filing Documents
- f8k_010424.htm (8-K) — 28KB
- 0001171843-24-000073.txt ( ) — 198KB
- poai-20231228.xsd (EX-101.SCH) — 3KB
- poai-20231228_lab.xml (EX-101.LAB) — 33KB
- poai-20231228_pre.xml (EX-101.PRE) — 22KB
- f8k_010424_htm.xml (XML) — 3KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. Predictive Oncology Inc. (the "Company") held its Annual Meeting of Stockholders on December 28, 2023 (the "Annual Meeting"). There were 4,063,081 shares of common stock outstanding and entitled to vote as of November 14, 2023, the record date for the Annual Meeting. The results of the matters submitted to a vote of the stockholders at the Annual Meeting are set forth below. 1. Election of three Class II director nominees. The Company's stockholders elected Gregory St. Clair, Sr., Nancy Chung-Welch, Ph.D. and Matthew J. Hawryluk, Ph.D. as Class II directors, each to serve for a three-year term that expires at the annual meeting of stockholders held in 2026 or until such director's successor has been duly elected or appointed and qualified, or until their earlier resignation or removal, by the following votes: Nominee For Withheld Broker Non-Votes Gregory St. Clair, Sr. 611,841 270,143 1,023,553 Nancy Chung-Welch, Ph.D. 599,750 282,234 1,023,553 Matthew J. Hawryluk, Ph.D. 673,106 208,877 1,023,553 2. Ratification of the appointment of BDO USA, P.C. to serve as the Company's independent registered public accounting firm. The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent auditor for 2023. The voting results were as follows: For Against Abstain 1,628,338 265,740 11,459 3. Proposal to approve the 2023 Equity Incentive Plan. The Company's stockholders did not approve the 2023 Equity Incentive Plane. The voting results were as follows: For Against Abstain Broker Non-Votes 432,129 435,447 14,408 1,023,553 4. Proposal to approve a non-binding advisory resolution on the compensation of the Company's named executive officers. The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. The voting results were as follows: For Against Abstain Broker Non
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PREDICTIVE ONCOLOGY inc. Date: January 4, 2024 By: /s/ Josh Blacher Name: Josh Blacher Title: Interim Chief Financial Officer